Core Viewpoint - The article discusses significant developments in the GLP-1 receptor agonist market, highlighting recent financing events and advancements in drug development aimed at obesity and type 2 diabetes treatment [4][6]. Group 1: Company Developments - On January 20, 2026, Gilead Sciences announced the selection of a new generation of monthly subcutaneous GLP-1R/GIPR/GCGR triple receptor agonists [4]. - On January 22, 2026, Jixing Pharmaceuticals completed a $287 million Series D financing round, focusing on the clinical development of its oral small molecule GLP-1 receptor agonist CX11 for obesity, overweight, and type 2 diabetes [4]. - The funds raised will support ongoing Phase II clinical trials for obesity and type 2 diabetes in the U.S. and prepare for subsequent Phase III trials [4]. Group 2: Product Insights - CX11 is an oral small molecule GLP-1 receptor agonist designed to provide a more convenient alternative to current injectable GLP-1 therapies [6]. - In December 2024, Jixing Pharmaceuticals acquired global rights (excluding China) to the CX11 project from Wenta Pharmaceutical, integrating it into their core pipeline [6]. - The CEO of Jixing Pharmaceuticals stated that this financing marks a significant milestone for the company, accelerating innovation in cardiovascular metabolic disease drug development and indicating a new phase of global growth [6]. Group 3: Investment Landscape - The financing round attracted notable international biopharmaceutical investors, including RTW Investments and Hengdian Capital, along with new investors such as SR One, TCGX, RA Capital Management, and others [6]. - This reflects a sustained interest from top-tier investors in the oral GLP-1 space, indicating confidence in the potential of these therapies [6].

瑞财经 王敏 1月23日，据箕星药业科技官微消息，Corxel Pharmaceuticals Limited箕星药业有限公司（下 文简称"箕星药业"）宣布已成功完成D1轮融资，募集资金高达2.87亿美元。 本轮融资新增投资者包括SR One、TCGX、Adage Capital Management、RA Capital Management、HBM Healthcare Investments、SymBiosis、Adage Capital Management、Invus、SilverArc Capital及其他投资 方。现有投资者RTW Investments和横店资本继续参投，显示其对CX11独特临床优势、箕星药业临床开 发能力及公司长期战略的持续信心。 本轮融资资金将主要用于推进其在研管线CX11的开发。CX11是一款具有独特优势的口服小分子GLP-1 RA，目前由箕星药业在美国开展一项其治疗肥胖及超重患者的2期临床试验，并由合作方闻泰医药在中 国开展一项3期临床试验。 此外，募集资金还将用于推进其它心血管代谢项目，包括针对急性缺血性脑卒中和高血压的管线开发。 随着本轮融资的完成，SR One、T ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Corxel Pharmaceuticals, a New Jersey-based biotechnology company, announced Thursday it raised $287 million in a Series D1 funding round meant to push an obesity drug into further testing. Corxel gained development rights to its lead program, an oral GLP-1 medicine called CX11, from the Chinese drugmaker Vincentage in 2024. CX11 is in mid-stage t ...